Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 181.35M | 185.24M | 191.49M | 206.28M | 194.60M | 176.90M |
Gross Profit | 85.20M | 91.47M | 30.56M | 140.58M | 144.33M | 127.61M |
EBITDA | -28.32M | 12.05M | 9.89M | 22.48M | 15.20M | -13.53M |
Net Income | -30.52M | -30.30M | -1.57M | 36.78M | 14.97M | -1.69M |
Balance Sheet | ||||||
Total Assets | 131.07M | 101.78M | 122.76M | 119.98M | 107.86M | 119.50M |
Cash, Cash Equivalents and Short-Term Investments | 18.36M | 9.93M | 18.36M | 10.36M | 11.91M | 29.41M |
Total Debt | 28.51M | 24.60M | 28.51M | 22.32M | 30.77M | 55.06M |
Total Liabilities | 111.22M | 80.09M | 102.90M | 101.18M | 122.85M | 162.90M |
Stockholders Equity | 19.86M | 21.69M | 19.86M | 18.81M | -14.99M | -43.40M |
Cash Flow | ||||||
Free Cash Flow | -4.39M | -6.73M | 7.67M | 22.99M | -4.81M | -10.54M |
Operating Cash Flow | -1.80M | -2.99M | 10.48M | 28.79M | -1.76M | -7.84M |
Investing Cash Flow | -3.32M | -3.74M | -2.31M | -11.49M | -2.90M | -775.00K |
Financing Cash Flow | 4.15M | -419.00K | -3.22M | -15.82M | -13.41M | 7.31M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | $729.71M | 13.08 | 9.10% | 7.13% | -2.69% | 61.73% | |
61 Neutral | $93.07M | ― | -16.55% | ― | -2.67% | 21.65% | |
58 Neutral | $1.34B | 4.20 | -2.93% | 7.41% | 3.67% | -51.13% | |
55 Neutral | $26.98M | ― | -12.15% | ― | 17.04% | -2188.42% | |
45 Neutral | $28.72M | ― | -147.49% | ― | -4.46% | -3053.30% | |
41 Neutral | $42.37M | ― | -123.16% | ― | -15.07% | 33.40% | |
$4.04M | ― | ― | ― | ― |
On June 24, 2025, Harte Hanks, Inc. extended its $25 million secured revolving line of credit with Texas Capital Bank, now maturing in June 2028. This extension, which includes an option to increase commitments by $10 million, enhances the company’s financial flexibility and supports its growth initiatives. Additionally, David Fisher was appointed as President, effective June 2, 2025, to oversee the company’s business segments and lead its transformation initiative, Project Elevate.
The most recent analyst rating on (HHS) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Harte-Hanks stock, see the HHS Stock Forecast page.
At the Harte Hanks 2025 Annual Meeting of Stockholders held on May 22, 2025, stockholders voted on key governance and operational matters. Four board nominees were elected to serve until the 2026 annual meeting, and the compensation of named executive officers was approved on a non-binding advisory basis. Additionally, the selection of Wolf & Company P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
The most recent analyst rating on (HHS) stock is a Buy with a $17.50 price target. To see the full list of analyst forecasts on Harte-Hanks stock, see the HHS Stock Forecast page.